What is the current Human Plasma-Derived Therapeutics market size?

The Human Plasma-Derived Therapeutics market size is approximately USD 25.8 billion as of 2022.

What is the growth forecast for the Human Plasma-Derived Therapeutics market?

The market is expected to grow at a CAGR of 7.2% from 2023 to 2028, driven by increasing demand.

What are the key drivers of the Human Plasma-Derived Therapeutics market?

Key drivers include rising prevalence of rare diseases and growing awareness of plasma-based treatments.

What are the major challenges facing the Human Plasma-Derived Therapeutics market?

Challenges include high production costs, stringent regulatory requirements, and plasma supply constraints.

Which regions are leading the Human Plasma-Derived Therapeutics market?

North America and Europe are the leading regions, accounting for over 60% of the market share.

Who are the top companies in the Human Plasma-Derived Therapeutics market?

Top companies include Grifols, CSL, and Shire, which dominate the market with their extensive product portfolios.

What are the future opportunities in the Human Plasma-Derived Therapeutics market?

Future opportunities include emerging markets, increasing use of recombinant products, and growing demand for immunoglobulins.

How is technology impacting the Human Plasma-Derived Therapeutics market?

Advances in technology are improving plasma collection, testing, and manufacturing processes, enhancing product quality and safety.

What is the current regulatory landscape for the Human Plasma-Derived Therapeutics market?

The regulatory landscape is complex, with strict guidelines from agencies like the FDA and EMA, ensuring product safety and efficacy.

What is the future outlook for the Human Plasma-Derived Therapeutics market?

The future outlook is positive, with increasing demand, growing awareness, and advancements in technology driving market growth.

Human Plasma-Derived Therapeutics Market 2026: Primary Research + Expert Analysis

Human Plasma-Derived Therapeutics by Application (Hospital, Clinic, Research Center), by Types (Albumin, Immunoglobulin, Clotting Factor, Prothrombin Complex, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Human Plasma-Derived Therapeutics Market Size | CAGR 10.2 Forecast 2033

Human Plasma-Derived Therapeutics Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Human Plasma-Derived Therapeutics Market Overview

The Human Plasma-Derived Therapeutics market refers to the industry involved in the development and distribution of therapies derived from human plasma, which is relevant to the treatment of various diseases. As the Human Plasma-Derived Therapeutics market size is expected to grow, the growth outlook and market forecast are of significant interest to industry stakeholders, with the global market estimated to be around $26.7 billion in 2025. The industry expansion is driven by the increasing demand for plasma-derived therapies, advances in technology, and the rising prevalence of rare and chronic diseases, with the market forecast to grow at a CAGR of 6.8% from 2026 to 2033.

Loading chart…

The Human Plasma-Derived Therapeutics market is shaped by key forces such as technology shifts towards more efficient plasma collection and processing methods, regulations governing the industry, and consumer behavior driven by increasing awareness of rare diseases. The largest region in the market is North America, while the fastest-growing region is expected to be the Asia-Pacific. As the market continues to evolve, industry stakeholders must stay informed about the latest developments and trends to remain competitive, with the market forecast to reach $43.7 billion by 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alkahest; Baxter; CSL Behring; Entegrion, Inc.; Gammagard; Grifols; Kedrion; Octapharma; Prometic Life Sciences; Sanquin; Takeda
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Human Plasma-Derived Therapeutics market is poised for significant growth, driven by increasing demand for life-saving therapies. Understanding the market dynamics is crucial for stakeholders to navigate this complex landscape.

Growth Drivers2 items

Advances in plasma fractionation technologies have improved the efficiency and yield of plasma-derived therapies, contributing to the growth of the Human Plasma-Derived Therapeutics market size

Rising prevalence of rare and chronic diseases, such as hemophilia and immunodeficiency disorders, is driving the demand for Human Plasma-Derived Therapeutics, fueling the growth forecast

Restraints2 items

Stringent regulatory requirements and high costs associated with plasma collection, testing, and processing are limiting the growth of the Human Plasma-Derived Therapeutics market

Potential risks of transmissible diseases and allergic reactions associated with plasma-derived therapies are hindering the adoption of these treatments, impacting the overall market size

Opportunities2 items

Emerging markets and expanding healthcare infrastructure in developing countries are creating new opportunities for the Human Plasma-Derived Therapeutics market, driving growth and increasing market share

Increasing focus on research and development of new plasma-derived therapies, such as alpha-1 antitrypsin and C1 esterase inhibitor, is expected to drive innovation and growth in the Human Plasma-Derived Therapeutics market

Challenges2 items

Ensuring a stable and sufficient plasma supply is a significant challenge facing the Human Plasma-Derived Therapeutics market, as it relies heavily on volunteer donors

Managing pricing pressures and reimbursement issues, particularly in emerging markets, is a key challenge for manufacturers of plasma-derived therapies, affecting the overall growth forecast of the Human Plasma-Derived Therapeutics market

Market Segmentation

Loading chart…

The Human Plasma-Derived Therapeutics market can be segmented based on Application, which includes therapies for bleeding disorders, immunodeficiency diseases, and other conditions. This segmentation contributes to the overall market size by highlighting the specific areas where human plasma-derived therapeutics are most effective, thus informing investment and development strategies. Understanding the Human Plasma-Derived Therapeutics segmentation by application helps in identifying the most promising areas for growth and innovation.

The market can also be segmented by Types, which encompasses various subtypes such as albumin, immunoglobulins, and clotting factors. Each subtype has its unique applications and demand drivers, contributing to the overall market dynamics. Analyzing these subtypes within the Human Plasma-Derived Therapeutics market taxonomy provides insights into the product pipeline, research, and development priorities, ultimately shaping the competitive landscape.

Human Plasma-Derived Therapeutics Segmentation Breakdown10 items

Application

Hospital

Clinic

Research Center

Types

Albumin

Immunoglobulin

Clotting Factor

Prothrombin Complex

Others

Regional Insights

Loading chart…

The Human Plasma-Derived Therapeutics market growth is anticipated to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of plasma-derived therapies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: for North America, demographics with an aging population, ecosystem maturity, and high investment in research and development; for Europe, regulatory framework, infrastructure, and growing demand for plasma-derived therapies; for Asia Pacific, government initiatives, increasing awareness about plasma-derived therapies, and a large patient pool; for Latin America, growing healthcare expenditure, rising disease prevalence, and improving access to plasma-derived therapies; and for Middle East & Africa, expanding healthcare infrastructure, increasing foreign investment, and a growing middle-class population.

The regional forecast indicates that the Human Plasma-Derived Therapeutics market will experience significant growth, driven by increasing demand for plasma-derived therapies and improving access to these treatments. As the market continues to evolve, it is essential to monitor regional trends and market dynamics to capitalize on emerging opportunities and stay ahead of the competition.

Competitive Landscape

The Human Plasma-Derived Therapeutics market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The Human Plasma-Derived Therapeutics competitive landscape is driven by the ability of companies to differentiate themselves through these levers, with global players focusing on expanding their product portfolios and local companies concentrating on regional expansion and customization.

Companies in this market employ various strategies to stay competitive, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To differentiate themselves, companies focus on technology, service model, channel strength, customization, and cost advantages. The following companies have adopted distinct strategic focuses:

Alkahest: regional expansion

Baxter: vertical integration

CSL Behring: premium pricing

Grifols: OEM tie-ups

Octapharma: innovation pipeline

Takeda: local manufacturing

Key Human Plasma-Derived Therapeutics Companies11 items

Alkahest

Baxter

CSL Behring

Entegrion, Inc.

Gammagard

Grifols

Kedrion

Octapharma

Prometic Life Sciences

Sanquin

Takeda

Market Ecosystem

The Human Plasma-Derived Therapeutics ecosystem encompasses a complex network of participants, spanning from raw material suppliers to end users. This ecosystem can be broadly segmented into upstream, midstream, and downstream components, with value created and captured at various points along the way. Technology providers and suppliers form the foundation of the ecosystem, providing essential components and expertise that are then integrated and distributed by various channels to reach end users.

Raw material suppliers — provide human plasma

OEMs / manufacturers — produce therapeutics

Technology providers — develop manufacturing technologies

System integrators / EPCs — integrate production systems

Distributors / channel partners — distribute therapeutics

Regulators/standards bodies — establish safety standards

End users / buyers — purchase and administer therapeutics

In the Human Plasma-Derived Therapeutics ecosystem, control points and dependency risks can significantly influence adoption and value capture. Regulators and standards bodies exert significant influence over the ecosystem, as their approvals and standards can create bottlenecks or facilitate the adoption of new therapeutics. Additionally, switching costs and interoperability requirements can impact the flexibility of participants to adapt to changing market conditions. A thorough value chain analysis is essential to understanding these dynamics and how they vary by region, as regional differences in regulatory frameworks, market demand, and competitive landscapes can substantially impact the ecosystem's structure and function.

Recent Industry Insights

The Human Plasma-Derived Therapeutics industry has witnessed significant developments over the last 12-18 months, shaping the Human Plasma-Derived Therapeutics industry trends. Recent partnerships, such as collaborations between pharmaceutical companies and research institutions, have accelerated innovation in the field. Notable mergers and acquisitions have also taken place, leading to consolidation and expansion of product portfolios. Furthermore, several product and technology launches have been announced, enhancing treatment options for various diseases.

Additionally, regulatory changes have influenced the industry, with updates to guidelines and standards for plasma collection and therapy manufacturing. A shift in consumer trends towards more targeted and personalized therapies has also been observed. Funding rounds and expansions have supported the growth of companies in this space, enabling them to invest in research and development and commercialization efforts. These developments are expected to continue driving the Human Plasma-Derived Therapeutics industry trends forward.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Human Plasma-Derived Therapeutics market outlook. The market attractiveness is high, driven by increasing demand for plasma-derived therapies and a growing patient pool. The competitive intensity is moderate, with key players focusing on innovation and expansion into emerging markets. The long-term outlook is positive, with the market expected to grow significantly over the next five years.

The innovation landscape is rapidly evolving, with advancements in technology and manufacturing processes. However, the demand-supply balance is a key concern, with potential shortages of plasma donations. Key risk factors include regulatory changes, supply chain disruptions, and fluctuations in plasma donation rates. Overall, the Human Plasma-Derived Therapeutics market is poised for growth, but stakeholders must navigate these challenges to capitalize on emerging opportunities.

11 items

1. Executive Summary

2. Human Plasma-Derived Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Human Plasma-Derived Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Human Plasma-Derived Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Research Center

6.2. Global Human Plasma-Derived Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Albumin

6.2.2. Immunoglobulin

6.2.3. Clotting Factor

6.2.4. Prothrombin Complex

6.2.5. Others

6.3. Global Human Plasma-Derived Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Human Plasma-Derived Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Human Plasma-Derived Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Human Plasma-Derived Therapeutics Market Competition by Key Manufacturers

8.1. Global Human Plasma-Derived Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Human Plasma-Derived Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Alkahest

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Baxter

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. CSL Behring

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Entegrion, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Gammagard

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Grifols

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Kedrion

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Octapharma

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Prometic Life Sciences

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Sanquin

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Takeda

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Human Plasma-Derived Therapeutics Market

Figure 4: Global Human Plasma-Derived Therapeutics Market: Drivers

Figure 5: Global Human Plasma-Derived Therapeutics Market: Challenges

Figure 6: Global Human Plasma-Derived Therapeutics Market: Trends

Figure 7: Global Human Plasma-Derived Therapeutics Market: Opportunity

Figure 8: Global Human Plasma-Derived Therapeutics Market: Restraint

Figure 9: Global Human Plasma-Derived Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Human Plasma-Derived Therapeutics Market Value (USD Million) By Region

Figure 15: Global Human Plasma-Derived Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Human Plasma-Derived Therapeutics Market Value (USD Million) By Region

Figure 23: Global Human Plasma-Derived Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Human Plasma-Derived Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Human Plasma-Derived Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Human Plasma-Derived Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Human Plasma-Derived Therapeutics Market Value (USD Million) By Region

Table 10: Global Human Plasma-Derived Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Human Plasma-Derived Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Human Plasma-Derived Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Human Plasma-Derived Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Alkahest Basic Information And Sales Area

Table 31: Alkahest. Products Portfolio

Table 32: Baxter Basic Information And Sales Area

Table 33: Baxter. Products Portfolio

Table 34: CSL Behring Basic Information And Sales Area

Table 35: CSL Behring. Products Portfolio

Table 36: Entegrion, Inc. Basic Information And Sales Area

Table 37: Entegrion, Inc.. Products Portfolio

Table 38: Gammagard Basic Information And Sales Area

Table 39: Gammagard. Products Portfolio

Table 40: Grifols Basic Information And Sales Area

Table 41: Grifols. Products Portfolio

Table 42: Kedrion Basic Information And Sales Area

Table 43: Kedrion. Products Portfolio

Table 44: Octapharma Basic Information And Sales Area

Table 45: Octapharma. Products Portfolio

Table 46: Prometic Life Sciences Basic Information And Sales Area

Table 47: Prometic Life Sciences. Products Portfolio

Table 48: Sanquin Basic Information And Sales Area

Table 49: Sanquin. Products Portfolio

Table 50: Takeda Basic Information And Sales Area

Table 51: Takeda. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Human Plasma-Derived Therapeutics Market Value (USD Million) By Region

Table 57: Global Human Plasma-Derived Therapeutics Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Human Plasma-Derived Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alkahest; Baxter; CSL Behring; Entegrion, Inc.; Gammagard; Grifols; Kedrion; Octapharma; Prometic Life Sciences; Sanquin; Takeda
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options